Mucosal NOD2 expression and NF-κB activation in pediatric Crohn's disease

Inflammatory Bowel Diseases

Volumn 14, Issue 3, 2008, Pages 295-302

  Stronati, Laura ^a   Negroni, Anna ^a   Merola, Paola ^a   Pannone, Veronica ^b   Borrelli, Osvaldo ^b   Cirulli, Manuela ^b   Annese, Vito ^c   Cucchiara, Salvatore ^b,d  

^a Section of Toxicology and Biomedical Sciences   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Children; Crohn's disease; Inflammation; Innate immunity; Intestinal mucosa

Indexed keywords

AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; MESALAZINE; MESSENGER RNA; METHOTREXATE; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BINDING AFFINITY; CHILD HEALTH CARE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DNA SEQUENCE; ENDOSCOPY; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; INTESTINE MUCOSA; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BIOPSY; BLOTTING, WESTERN; CHILD; COLONOSCOPY; CROHN DISEASE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GENE EXPRESSION; GENOTYPE; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; NF-KAPPA B; NOD2 SIGNALING ADAPTOR PROTEIN; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149164236     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20332     Document Type: Article

References (42)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
2. Bamias G, Nyce MR, De La Rue SA, et al. American College of Physicians; American Physiological Society. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern. 2005;143:895-904.
3. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
4. Abreu MT, Arditi M. Innate immunity and too-like receptors: clinical implications of basic science research. J Pediatr. 2004;144:421-429.
5. Reuter BK, Pizarro TT. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol. 2004;34:2347-2355.
6. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut. 2005;54:1182-1193.
7. Gaya DR, Russell RK, Nimmo ER, et al. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet. 2006;367:1271-1284.
8. Inohara N, Chamaillard M, McDonald C, et al. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem. 2005;74:355-383.
9. Ting JP, Davis BK. CATERPILLER: a novel gene family important in immunity, cell death and diseases. Annu Rev Immunol. 2005;23:387-414.
10. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
11. Chamaillard M, Philpott D, Girardin SE, et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A. 2003;100:3455-3460.
12. Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature. 2002;416:194-199.
13. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem. 2001;276:4812-4818.
14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
15. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
16. Kramer M, Netea MG, de Jong DJ, et al. Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. J Leukoc Biol. 2006;79:860-866.
17. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-734.
18. Maeda S, Hsu LC, Liu H. et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1 beta processing. Science.2005; 307:734-738.
19. van Heel DA, Ghosh S, Butler M, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet.2005; 365:1794-1796.
20. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800-808.
21. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993-1000.
22. Inflammatory Bowel Disease Group of ESPGHAN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1-7.
23. Hyams JS, Mandel F, Ferry GD, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
24. Palmieri O, Toth S, Ferraris A, et al. CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. Clin Chem. 2003;49:1675-1679.
25. Baldi A, De Luca A, Claudio PP, et al. The RB2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J Cell Biochem. 1995;59:402-408.
26. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut. 1998;42:477-484.
27. Rosenstiel P, Fantini M, Bräutigam K, et al. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in the human epithelial cells. Gastroenterology. 2003;124:1001-1009.
28. Rescigno M, Nieuwenhuis EE. The role of altered microbial signaling via mutant NODs in intestinal inflammation. Curr Opin Gastroenterol. 2007;23:21-26.
29. Eckmann L. Sensor molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol. 2006;22:95-101.
30. Kufer TA, Banks DJ, Philpott DJ. Innate immune sensing of microbes by Nod proteins. Ann N Y Acad Sci. 2006;1072:19-27.
31. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006;442:39-44.
32. Strober W, Murray PJ, Kitani A, et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6:9-20.
33. Bousvaros A, Sylvester F, Kugathasan S, et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:885-913.
34. Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis. 2002;8:112-128.
35. Berrebi D, Maudinas R, Hugot JP, et al. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut. 2003;52:840-846.
36. Gutierrez G, Pipaon C, Inohara, et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kB activation. J Biol Chem. 2002;277:41701-41705.
37. Hisamatsu T, Suzuki M, Reinecker H, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993-1000.
38. Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006;8:279-302.
39. Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents. Nat Clin Pract Gastroenterol Hepatol. 2005;2:572-579.
40. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10:745-750.
41. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-324.
42. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.